saxenda glp 1 agonist (Liraglutide) WEIGHT LOSS DRUGS – DO
Description
Figure S3
Androgenic alopecia requires ongoing treatment
In these cases, clinicians should assume a higher risk of retained gastric contents when GLP-1 exposure is known or suspected, especially if the patient has gastrointestinal symptoms
At 12 months, body mass decreased by 4%, WC decreased by 3.2 cm, and BMI decreased by 1.74 kg/m
[DOI] [PMC free article] [PubMed] [Google Scholar] 47.Park HC, Lee YK, Cho A, et al
.webp)
